Last update 24 May 2025

Cyclin B1/WT-1/CEF-loaded dendritic cell vaccine(Baylor Research Institute)

Overview

Basic Info

Drug Type
Therapeutic vaccine, Dendritic cell vaccine
Synonyms-
Target
CCNB1 x WT1
Action
inhibitors
Mechanism
CCNB1 inhibitors(cyclin B1 inhibitors), WT1 inhibitors(Wilms' Tumour 1 inhibitors)
Therapeutic Areas
NeoplasmsSkin and Musculoskeletal Diseases
Active Indication-
Inactive Indication
Advanced Triple-Negative Breast CarcinomaER-positive/HER2-negative Breast Cancer
Originator Organization
Baylor Research Institute
Active Organization-
Inactive Organization
Baylor Research Institute
License Organization-
Drug Highest PhasePendingPhase 1/2
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with Cyclin B1/WT-1/CEF-loaded dendritic cell vaccine(Baylor Research Institute)
NCT02018458
/ CompletedPhase 1/2IIT
Pilot Safety Trial of Preoperative Chemotherapy Combined With Dendritic Cell Vaccine in Patients With Locally Advanced, Triple-Negative Breast Cancer or ER-Positive, Her2-Negative Breast Cancer
100 Clinical Results associated with Cyclin B1/WT-1/CEF-loaded dendritic cell vaccine(Baylor Research Institute)
Login to view more data
100 Translational Medicine associated with Cyclin B1/WT-1/CEF-loaded dendritic cell vaccine(Baylor Research Institute)
Login to view more data
100 Patents (Medical) associated with Cyclin B1/WT-1/CEF-loaded dendritic cell vaccine(Baylor Research Institute)
Login to view more data
100 Deals associated with Cyclin B1/WT-1/CEF-loaded dendritic cell vaccine(Baylor Research Institute)
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Triple-Negative Breast CarcinomaPhase 2
United States
Baylor Research Institute
01 May 2014
ER-positive/HER2-negative Breast CancerPhase 2
United States
Baylor Research Institute
01 May 2014
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NCT02018458 (CTgov)
Phase 1/2
ER-positive/HER2-negative Breast Cancer | Advanced Triple-Negative Breast Carcinoma
10
kgykpocchv = jrtkwckkmy tcgkaxjequ (dgvrysgsfm, affqnzqkfu - ihqzpkhokm)
View more
-
13 Mar 2020
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free